Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned

May 11, 2023
Kyowa Kirin said on May 10 that it has downwardly revised its profit forecast for the fiscal year through December 2023 accompanying its decision to discontinue the development of bardoxolone methyl (RTA402) for diabetic kidney disease (DKD) and all other...read more